Tandospirone citrate (SM-3997 citrate) is a potent and selective 5-HT1A receptor partial agonist (Ki : 27 nM)

5-HT1A:27 nM（ki）

在临床试验中, 与安慰剂相比, 使用tandospirone治疗组在第1、2、4周时腹部总评分的改善显著更大。特别是在第4周, tandospirone组在上腹部疼痛（P=0.02）和不适（P=0.002）方面的改善显著更为明显。此外, 在第3（P=0.017）和第4周（P=0.0016）, 活性治疗组的应答者比例显著高于对照组。两个研究组在STAI得分上（P<0.0001）以及SF-8的大部分问题上（P=0.04）均报告了显著改善。研究中没有报告严重不良事件, 两组的发生率相似[1]。

In this double-blind, placebo-controlled, multicenter study, FD patients were randomized to treatment with 10 mg t.i.d. tandospirone citrate or to placebo for 4 weeks. The primary end point was change in abdominal symptom scores. The difference in the proportion of responders (a total abdominal symptom score of 0 or 1) was also assessed. The quality-of-life questionnaire, the SF-8, and a psychological test questionnaire, the State-Trait Anxiety Inventory (STAI), were completed at baseline and at weekly intervals[1]